Home / Centerstage / 2016 / march / Week 3 /
Affymetrix, a provider of cellular and genetic analysis products, rejects a rival bid to Thermo Fisher's merger plan and proceeds with Thermo Fisher's acquisition for $14.00 per share in cash. The transaction, valued at approximately $1.3 billion, receives unanimous approval from both companies' boards of directors. The deal aims to enhance Thermo Fisher's offerings in the field of genetic analysis and strengthen its position in the market.
Sunday, 27 March, 2016